Neoantigen Targeted Therapies Market is estimated to be worth USD 3 Billion in 2030

Basic information
Date of placement
  • <p>Neoantigen Targeted
Therapies Market is estimated to be worth USD 3 Billion in 2030</p> photo

Advances in bioinformatics and genomic data analysis have enabled the identification of cancer antigens that are generally overlooked during immune surveillance; these neoantigens have been shown to possess substantial therapeutic potential Roots Analysis is pleased to announce the publication of its recent study, titled, “Neoantigen Targeted Therapies, 2019-2030.” The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: · A detailed assessment of the current market landscape of developers engaged in the development of neoantigen targeted therapies. · Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products). · A detailed publication analysis of close to 300 peer-reviewed, scientific articles published during the period 2015-2019 (till February), highlighting the research focus within the industry. · An in-depth analysis of the various patents that have been filed / granted related to neoantigens. · An analysis of the various partnerships pertaining to neoantigen targeting therapies. · An analysis of the investments made at various stages of development in companies that are focused on developing neoantigen targeted therapies. For more information, please visit Neoantigen Targeted Therapies Market | Industry Analysis | Market Size | 2030 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) Target Disease Indication · Bone and Cartilage Cancer · Colorectal Cancer · Head and Neck Cancer · Renal Carcinoma · Hepatocellular Carcinoma · Lung Cancer · Gynecological Cancer · Others Type of Treatment · Personalized · Off-the-shelf Type of Immunotherapy · Dendritic Cell Vaccine · DNA / RNA-based Vaccine · Protein / Peptide-based Vaccine · TIL-based Therapy Route of Administration · Intradermal · Intravenous · Subcutaneous · Others Key Geographical Region · North America (US) · Europe (UK, Germany, France, Italy, and Spain · Rest of the World Transcripts of interviews held with the following senior level representatives of stakeholder companies: · Gabriel Nistor, Chief Scientific Officer, AIVITA Biomedical · Ella Sorani, Vice President Research and Development, BioLineRx · Heinz Lubenau, Chief Operating Officer and Co-Founder, VAXIMM Key companies covered in the report · Bavarian Nordic · Genocea Biosciences · Gradalis · Immunicum · Immunovative Therapies · Iovance Biotherapeutics · Medigene · Neon Therapeutics · Precision Biologics · Vaxon Biotech For more information, please click on the following link:

Dislike 0
Like 0
Someone is typing...
I agree and close
x We use cookies to measure visitor statistics, personalize ads and customize the functionality of the site. You agree to this by using the website